BC30® (GanedenBC30® Bacillus coagulans GBI-30, 6086)

Bacillus coagulans
Evidence Level
Moderate
3 Clinical Trials
5 Documented Benefits
3/5 Evidence Score

BC30® (originally GanedenBC30®, now part of Kerry Group following the Ganeden acquisition) is the patented Bacillus coagulans GBI-30, 6086 probiotic — a spore-forming, lactic acid-producing organism selected for exceptional manufacturing and gastric stability. The spore form survives heat, pressure, and acidic environments, then germinates in the small intestine to deliver active probiotic activity. Over 30 published human trials investigate BC30® across gas and bloating, irritable bowel symptoms, immune function, exercise-related muscle damage and recovery, and protein/amino acid absorption — making it one of the best-documented spore-forming probiotic strains.

Studied Dose 1–2 billion CFU/day for gut and immune support trials (typically once daily). Muscle recovery and protein absorption trials commonly co-dose BC30® (1 billion CFU) with a protein meal. Heat-stable spores require no refrigeration.
Active Compound Bacillus coagulans GBI-30, 6086 spores — BC30® / GanedenBC30® (Kerry Group); spore-forming, heat- and shelf-stable; typically 1 billion CFU per serving in finished products

Benefits

Relief of post-prandial gas and bloating

Randomized trials report that BC30® significantly improves abdominal pain and overall gastrointestinal symptom scores in adults experiencing post-prandial intestinal gas. The spore-forming format reliably reaches the intestine, supporting consistent symptom relief over weeks of daily use.

Support for protein absorption from plant proteins

Co-ingestion of BC30® with plant protein (rice and pea blend) has been associated with greater post-meal amino acid availability in older women, consistent with the hypothesis that BC30® supports digestive efficiency from plant-based protein sources that are otherwise less efficiently digested than animal protein.

Reduced exercise-induced muscle damage and faster recovery

When co-ingested with casein protein after intense exercise, BC30® supplementation has been associated with reductions in markers of muscle damage and perceived muscle soreness, along with improvements in subjective recovery, supporting use as an adjunct to athletic recovery nutrition.

Adjunctive support in rheumatoid arthritis symptom management

A pilot trial in adults with rheumatoid arthritis on standard medication reported improvements in pain scale and patient pain assessment scores with BC30® versus placebo over 60 days. Effects are modest and adjunctive — not a substitute for standard disease-modifying therapy — but suggest immune-modulatory activity at the mucosal level.

Shelf-stable, room-temperature delivery

BC30®'s spore-forming biology allows it to survive food manufacturing, baking, and shelf storage at room temperature, then germinate in the intestine. This enables incorporation into shelf-stable bars, drinks, and snacks where conventional Lactobacillus or Bifidobacterium probiotics would not survive.

Mechanism of action

1

Spore-form survival and intestinal germination

Endospores formed by Bacillus coagulans are highly resistant to heat, gastric acid, and bile. Spores transit the stomach largely intact, then germinate in the small intestine where vegetative cells become metabolically active, producing lactic acid and other fermentation products that influence the local microbial environment.

2

Lactic acid production and pH modulation

Germinated BC30® cells ferment available carbohydrates and produce lactic acid, lowering local intestinal pH. This shift in pH and short-chain fatty acid milieu can inhibit pH-sensitive pathogens, support beneficial commensals, and modulate enzyme activity involved in macronutrient digestion.

3

Mucosal immune modulation

Probiotic spore-forming bacteria interact with gut-associated lymphoid tissue, dendritic cells, and pattern-recognition receptors, modulating cytokine output and regulatory T-cell activity. These signals are implicated in observed effects on inflammation and adjunctive RA symptom benefits.

4

Protease and digestive enzyme activity

Vegetative BC30® cells produce proteolytic and carbohydrate-active enzymes that may complement endogenous digestion of plant proteins and complex carbohydrates, supporting more complete amino acid liberation when co-consumed with a protein meal.

Clinical trials

1
BC30® for Functional Intestinal Gas Symptoms

Prospective, randomized, double-blind, placebo-controlled, parallel-group, dual-site trial of BC30® versus placebo in 61 adults with post-prandial intestinal gas symptoms. Outcomes: Gastrointestinal Symptom Rating Scale (GSRS), abdominal pain subscores. Published in BMC Gastroenterology.

61 adults with post-prandial intestinal gas; randomized trial.

BC30® supplementation significantly improved the GSRS abdominal pain subscore versus placebo and produced overall reductions in functional gas symptoms, supporting the strain for non-specific gas, bloating, and abdominal pain in adults.

2
BC30® Co-Ingestion with Casein for Exercise Recovery

Randomized trial co-ingesting 20 g casein protein with or without 1 billion CFU BC30® in recreationally trained males following an intense exercise protocol. Outcomes: markers of muscle damage, soreness, and perceived recovery. Published in PeerJ.

Recreationally trained males; post-exercise recovery protocol.

BC30® co-ingested with casein was associated with reductions in markers of exercise-induced muscle damage and perceived muscle soreness, along with improvements in subjective recovery measures, supporting the strain as an adjunct to post-exercise nutrition.

3
BC30® for Amino Acid Absorption from Plant Protein in Older Women

Randomized trial co-ingesting a rice and pea plant protein blend with or without BC30® in older women. Outcomes: post-meal plasma amino acid concentrations over time. Published in Probiotics and Antimicrobial Proteins (peer-reviewed indexed via PubMed).

Older women consuming standardized plant protein meal.

Co-ingestion of BC30® with the rice/pea plant protein blend was associated with greater post-meal plasma amino acid availability versus protein alone, supporting use of BC30® alongside plant-based protein for older adults seeking improved amino acid uptake.

Side effects and drug interactions

Common Potential side effects

Generally well tolerated at 1–2 billion CFU/day.
Transient bloating or mild gas in the first few days of use.
Rare allergic-type reactions reported anecdotally.
Severely immunocompromised individuals should consult a clinician before use.
No notable adverse events reported in the published clinical trial base.

Important Drug interactions

Broad-spectrum antibiotics — may reduce viable probiotic activity; separate dosing by several hours.
Strong immunosuppressants (cyclosporine, tacrolimus) — use only with clinician oversight.
Anti-rejection regimens after organ transplant — discuss probiotic use with transplant team.
No notable interactions with common cardiovascular, diabetic, or thyroid medications.

Frequently asked questions about BC30® (GanedenBC30® Bacillus coagulans GBI-30, 6086)

What is the recommended dosage of BC30® (GanedenBC30® Bacillus coagulans GBI-30, 6086)?

The clinically studied dose for BC30® (GanedenBC30® Bacillus coagulans GBI-30, 6086) is 1–2 billion CFU/day for gut and immune support trials (typically once daily). Muscle recovery and protein absorption trials commonly co-dose BC30® (1 billion CFU) with a protein meal. Heat-stable spores require no refrigeration.. Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is BC30® (GanedenBC30® Bacillus coagulans GBI-30, 6086) used for?

BC30® (GanedenBC30® Bacillus coagulans GBI-30, 6086) is studied for relief of post-prandial gas and bloating, support for protein absorption from plant proteins, reduced exercise-induced muscle damage and faster recovery. Randomized trials report that BC30® significantly improves abdominal pain and overall gastrointestinal symptom scores in adults experiencing post-prandial intestinal gas.

Are there side effects from taking BC30® (GanedenBC30® Bacillus coagulans GBI-30, 6086)?

Reported potential side effects may include: Generally well tolerated at 1–2 billion CFU/day. Transient bloating or mild gas in the first few days of use. Always consult a healthcare provider before starting any new supplement, especially if you have underlying conditions or take medications.

Does BC30® (GanedenBC30® Bacillus coagulans GBI-30, 6086) interact with medications?

Known drug interactions may include: Broad-spectrum antibiotics — may reduce viable probiotic activity; separate dosing by several hours. Strong immunosuppressants (cyclosporine, tacrolimus) — use only with clinician oversight. Consult a pharmacist or healthcare provider if you take prescription medications.

Is BC30® (GanedenBC30® Bacillus coagulans GBI-30, 6086) good for gut health?

Yes, BC30® (GanedenBC30® Bacillus coagulans GBI-30, 6086) is researched for Gut Health support. Co-ingestion of BC30® with plant protein (rice and pea blend) has been associated with greater post-meal amino acid availability in older women, consistent with the hypothesis that BC30® supports digestive efficiency from plant-based protein sources that are otherwise less effici…

References(4 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Kalman DS, Schwartz HI, Alvarez P, Feldman S, Pezzullo JC, Krieger DR. A prospective, randomized, double-blind, placebo-controlled parallel-group dual site trial to evaluate the effects of a Bacillus coagulans-based product on functional intestinal gas symptoms. BMC Gastroenterol. 2009;9:85. doi: 10.1186/1471-230X-9-85.PubMedUsed to support: RCT in 61 adults with post-prandial gas — BC30® / GanedenBC30® significantly improved GSRS abdominal pain subscore (p=0.046) and overall symptom reduction vs placebo over the trial.
  2. Mandel DR, Eichas K, Holmes J. Bacillus coagulans: a viable adjunct therapy for relieving symptoms of rheumatoid arthritis according to a randomized, controlled trial. BMC Complement Altern Med. 2010;10:1. doi: 10.1186/1472-6882-10-1.PubMedUsed to support: Pilot RCT in 45 adults with rheumatoid arthritis on standard therapy — BC30® produced borderline-significant improvement in Patient Pain Assessment (p=0.052) and significant improvement in Pain Scale (p=0.046) vs placebo over 60 days, supporting adjunctive immune-modulatory effects.
  3. Jäger R, Shields KA, Lowery RP, De Souza EO, Partl JM, Hollmer C, Purpura M, Wilson JM. Probiotic Bacillus coagulans GBI-30, 6086 reduces exercise-induced muscle damage and increases recovery. PeerJ. 2016;4:e2276. doi: 10.7717/peerj.2276.PubMedUsed to support: RCT co-ingesting 20 g casein with BC30® post-exercise in recreationally trained males — BC30® was associated with reductions in markers of exercise-induced muscle damage and perceived soreness, with improved recovery vs casein alone.
  4. Jäger R, Zaragoza J, Purpura M, Iametti S, Marengo M, Tinsley GM, Anzalone AJ, Oliver JM, Fiore W, Biffi A, Urbina S, Taylor L. Probiotic Administration Increases Amino Acid Absorption from Plant Protein: a Placebo-Controlled, Randomized, Double-Blind, Multicenter, Crossover Study. Probiotics Antimicrob Proteins. 2020;12(4):1330-1339. doi: 10.1007/s12602-020-09656-5.PubMedUsed to support: RCT — co-ingestion of BC30® with plant-based protein increased post-meal amino acid availability versus protein alone, supporting use of BC30® alongside plant protein sources.